Generic substitution of antiepileptic drugs

Expert Review of Neurotherapeutics

Volumn 10, Issue 12, 2010, Pages 1887-1898

  Sander, Josemir W ^a,b   Ryvlin, Philippe ^c   Stefan, Hermann ^d,e   Booth, Daniel R ^f   Bauer, Jürgen ^g  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

^c HÔPITAL NEUROLOGIQUE   (France)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e UNIVERSITY HOSPITAL MARBURG   (Germany)

^f Bioscript Stirling Ltd   (United Kingdom)

^g UNIVERSITY OF BONN   (Germany)

Author keywords

AED; antiepileptic drugs; epilepsy; generic drugs; switching

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CIPROFLOXACIN; CLOBAZAM; CLONAZEPAM; CODEINE; FLUTICASONE PROPIONATE; GABAPENTIN; GENERIC DRUG; LAMOTRIGINE; NAPROXEN; PARACETAMOL; PHENYTOIN; PRIMIDONE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ANTICONVULSANT THERAPY; AREA UNDER THE CURVE; BIOEQUIVALENCE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INTERACTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPILEPSY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; HEALTH CARE COST; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAXIMUM PLASMA CONCENTRATION; PATIENT COMPLIANCE; REVIEW; SEIZURE; SHELF LIFE;

ANTICONVULSANTS; DRUG SUBSTITUTION; DRUGS, GENERIC; EPILEPSY; HUMANS; MALE; MEDICATION ADHERENCE; THERAPEUTIC EQUIVALENCY;

EID: 78649528076     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.163     Document Type: Review

References (106)

1. Forsgren L, Beghi E, Oun A, Sillanpaa M. The epidemiology of epilepsy in Europe-a systematic review. Eur. J. Neurol. 12 (4), 245-253 (2005).
2. Kobau R, Zahran H, Thurman DJ et al. Epilepsy surveillance among adults-19 States, Behavioral Risk Factor Surveillance System, 2005. MMWR Surveill. Summ. 57(6), 1-20 (2008).
3. Sander JW. The epidemiology of epilepsy revisited. Curr. Opin. Neurol. 16(2), 165-170 (2003).
4. French JA, Kanner AM, Bautista J et al. Effcacy and tolerability of the new antiepileptic drugs, II: treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 45(5), 410-423 (2004). (Pubitemid 38581554)
5. Kesselheim AS, Stedman MR, Bubrick EJ et al. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta analysis. Drugs 70(5), 605-621 (2010).
6. Guberman A, Corman C. Generic substitution for brand name antiepileptic drugs: a survey. Can. J. Neurol. Sci. 27(1), 37-43 (2000).
7. Berg MJ, Gross RA, Haskins LS, Zingaro WM, Tomaszewski KJ. Generic substitution in the treatment of epilepsy: patient and physician perceptions. Epilepsy Behav. 13(4), 693-699 (2008).
8. Håkonsen H, Eilertsen M, Borge H, Toverud EL. Generic substitution: additional challenge for adherence in hypertensive patients? Curr. Med. Res. Opin. 25(10), 2515-2521 (2009).
9. Chapman RH, Benner JS, Girase P et al. Generic and therapeutic statin switches and disruptions in therapy. Curr. Med. Res. Opin. 25(5), 1247-1260 (2009).
10. Crawford P, Feely M, Guberman A, Kramer G. Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure 15(3), 165-176 (2006).
11. Duh MS, Paradis PE, Latremouille-Viau D et al. The risks and costs of multiple-generic substitution of topiramate. Neurology 72(24), 2122-2129 (2009).
12. Stokes T, Shaw EJ, Juarez-Garcia A, Camosso-Stefnovic J, Baker R. Clinical Guidelines and Evidence Review for the Epilepsies: Diagnosis and Management in Adults and Children in Primary and Secondary Care. Royal College of General Practitioners, London, UK (2004).
13. American Academy of Neurology. Assessment: generic substitution for antiepileptic medication. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 40(11), 1641-1643 (1990).
14. Liow K, Barkley GL, Pollard JR, Harden CL, Bazil CW. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology 68(16), 1249-1250 (2007).
15. Endrenyi L, Midha KK. Individual bioequivalence-has its time come? Eur. J. Pharm. Sci. 6(4), 271-278 (1998).
16. Bialer M, Midha KK. Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability Epilepsia 51(6), 941-950 (2010).
17. Tothfalusi L, Speidl S, Endrenyi L. Exposure-response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets. Br. J. Clin. Pharmacol. 65(1), 110-122 (2007).
18. Cloyd JC, Marino S, Birnbaum AK. Factors affecting antiepileptic drug pharmacokinetics in community-dwelling elderly. Int. Rev. Neurobiol. 81, 201-210 (2007).
19. Gidal BE. Drug absorption in the elderly: biopharmaceutical considerations for the antiepileptic drugs. Epilepsy Res. 68(Suppl. 1), S65-S69 (2006).
20. Gilman JT, Duchowny M, Campo AE. Pharmacokinetic considerations in the treatment of childhood epilepsy. Paediatr. Drugs 5(4), 267-277 (2003).
21. Battino D, Estienne M, Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate. Clin. Pharmacokinet. 29(5), 341-369 (1995).
22. Battino D, Estienne M, Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: phenobarbital, primidone, valproic acid, ethosuximide and mesuximide. Clin. Pharmacokinet. 29(4), 257-286 (1995).
23. Lesser R P, Irace P, Kutt H et al. Enhanced gastrointestinal excretion of phenytoin in a patient with Crohn's disease. Epilepsia 25(3), 302-307 (1984).
24. Birnbaum AK. Pharmacokinetics of antiepileptic drugs in elderly nursing home residents. Int. Rev. Neurobiol. 81, 211-220 (2007).
25. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2(6), 347-356 (2003). (Pubitemid 38352562)
26. Perucca E. Clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fundam. Clin. Pharmacol. 15(6), 405-417 (2001).
27. Endrenyi L, Tothfalusi L. Do regulatory bioequivalence requirements adequately refect the therapeutic equivalence of modifed-release drug products? J. Pharm. Pharm. Sci. 13(1), 107-113 (2010).
28. Krauss GL, Davit BM, Caffo BS et al. Comparing bioequivalence of generic antiepilepsy drugs (AEDs). Neurology 74(Suppl. 2), Abstract A303 (2010).
29. Meyer MC, Straughn AB, Mhatre RM, Shah V P, Williams RL, Lesko LJ. The relative bioavailability and in vivo-in vitro correlations for four marketed carbamazepine tablets. Pharm. Res. 15(11), 1787-1791 (1998).
30. Meyer MC, Straughn AB, Jarvi EJ, Wood GC, Pelsor FR, Shah VP. The bioinequivalence of carbamazepine tablets with a history of clinical failures. Pharm. Res. 9(12), 1612-1616 (1992).
31. Silpakit O, Amornpichetkoon M, Kaojarern S. Comparative study of bioavailability and clinical effcacy of carbamazepine in epileptic patients. Ann. Pharmacother. 31(5), 548-552 (1997).
32. Soryal I, Richens A. Bioavailability and dissolution of proprietary and generic formulations of phenytoin. J. Neurol. Neurosurg. Psychiatry 55(8), 688-691 (1992).
33. Feely M, Crawford P, Kramer G, Guberman A. Risk management in epilepsy: generic substitution and continuity of supply. Eur. J. Hosp. Pharm. Sci. 11(4), 83-87 (2005).
34. Chuang K, Krauss GL, Cao YJ. Evaluating FDA bioequivalence standards for generic carbamazepine formulations. Presented at: AAN 61st Annual Meeting. Seattle, WA, USA, 25 April-2 May 2009 (Poster #P05 085).
35. European Parliament. Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community Code Relating to Medicinal Products for Human Use. European Parliament, Strasbourg, France (2004).
36. Schmidt D. Strategies to prevent overtreatment with antiepileptic drugs in patients with epilepsy. Epilepsy Res. 52(1), 61-69 (2002). (Pubitemid 35351533)
37. Bauer J, Kronisch C. [Medical treatment of epilepsy: hidden dimensions]. Nervenarzt 80(4), 386-398 (2009).
38. Lloyd A, McIntosh E, Price M. The importance of drug adverse effects compared with seizure control for people with epilepsy: a discrete choice experiment. Pharmacoeconomics 23(11), 1167-1181 (2005).
39. Wilner AN. Physicians underestimate the frequency of generic carbamazepine substitution: results of a survey and review of the problem. Epilepsy Behav. 3(6), 522-525 (2002).
40. IMS Health. What Is The Effect of Price Discount Contracts on Routine Care? IMS HEALTH GmbH & Co. OHG, Frankfurt/Main (2010).
41. Pawloski M, Kerling F, Hercksen I et al. Interim analysis of an ongoing prospective study: use of lamotrigine generic drugs: experiences of the Epilepsy Center Erlangen. Presented at: 27th International Epilepsy Congress. Singapore, 8-12 July (2007).
42. LeLorier J, Duh MS, Paradis PE et al. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy Neurology 70(22 Pt 2), 2179-2186 (2008).
43. Paradis PE, Latremouille-Viau D, Moore Y et al. Projected economic impact of clinical fndings of generic entry of topiramate on G4 European countries. Curr. Med. Res. Opin. 25(7), 1793-1805 (2009).
44. Paradis PE, Latrémouille-Viau D, Lefebvre P et al. Clinical consequences of generic substitution of topiramate. Presented at: 28th International Epilepsy Congress (ILAE). Budapest, Hungary 28 June-2 July (2009) (Poster P184).
45. Labiner DM, Paradis PE, Manjunath R et al. Generic antiepileptic drugs and associated medical resource utilization in the United States. Neurology 74(20), 1566-1574 (2010).
46. Welty TE, Pickering PR, Hale BC, Arazi R. Loss of seizure control associated with generic substitution of carbamazepine. Ann. Pharmacother. 26(6), 775-777 (1992).
47. Burkhardt RT, Leppik IE, Blesi K, Scott S, Gapany SR, Cloyd JC. Lower phenytoin serum levels in persons switched from brand to generic phenytoin. Neurology 63(8), 1494-1496 (2004).
48. Gilman JT, Alvarez LA, Duchowny M. Carbamazepine toxicity resulting from generic substitution. Neurology 43(12), 2696-2697 (1993).
49. Hartley R, Aleksandrowicz J, Ng PC, McLain B, Bowmer CJ, Forsythe WI. Breakthrough seizures with generic carbamazepine: a consequence of poorer bioavailability? Br. J. Clin. Pract. 44(7), 270-273 (1990).
50. MacDonald JT. Breakthrough seizure following substitution of Depakene capsules (Abbott) with a generic product. Neurology 37(12), 1885 (1987).
51. Wyllie E, Pippenger CE, Rothner AD. Increased seizure frequency with generic primidone. JAMA 258(9), 1216-1217 (1987).
52. Di Bonaventura C, Fattouch J, Fabbrini G, Manfredi M, Prencipe M, Giallonardo TA. Switching from branded to generic antiepileptic drugs as a confounding factor and unpredictable diagnostic pitfall in epilepsy management. Epileptic Disord. 9(4), 465-466 (2007).
53. Nielsen KA, Dahl M, Tommerup E, Wolf P. Comparative daily profles with different preparations of lamotrigine: a pilot investigation. Epilepsy Behav. 13(1), 127-130 (2008).
54. Berg MJ, Gross RA, Tomaszewski KJ, Zingaro WM, Haskins LS. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology 71(7), 525-530 (2008).
55. Andermann F, Duh MS, Gosselin A, Paradis PE. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 48(3), 464-469 (2007).
56. Devine ST, Weisbart E, Barron J, Behm A. Acute epilepsy exacerbations in patients switched between A-rated anti-epileptic drugs. Curr. Med. Res. Opin. 26(2), 455-463 (2010).
57. Wilner AN. Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav. 5(6), 995-998 (2004).
58. Biraben A, De TB, Semah F, Rouaud T [Use of generic anti-epilepsy drugs in France: survey of neurologists and review of the literature]. Rev. Neurol. (Paris) 163(4), 455-461 (2007).
59. Haskins LS, Tomaszewski KJ, Crawford P. Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsy. Epilepsy Behav. 7(1), 98-105 (2005).
60. Krämer G, Steinhoff BJ, Feucht M, Pfäffin M, May TW. [Experiences with generic drugs in epilepsy patients. Results of an internet-based questionnaire study in Germany, Austria, and Switzerland]. Akt. Neurol. 33, 431-438 (2006).
61. Crawford P, Hall WW, Chappell B, Collings J, Stewart A. Generic prescribing for epilepsy: is it safe? Seizure 5(1), 1-5 (1996).
62. McAuley J W, Chen AY, Elliott JO, Shneker BF. An assessment of patient and pharmacist knowledge of and attitudes toward reporting adverse drug events due to formulation switching in patients with epilepsy. Epilepsy Behav. 14(1), 113-117 (2009).
63. Papsdorf TB, Ablah E, Ram S, Sadler T, Liow K. Patient perception of generic antiepileptic drugs in the Midwestern United States. Epilepsy Behav. 14(1), 150-153 (2009).
64. Begley CE, Famulari M, Annegers JF et al. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia 41(3), 342-351 (2000).
65. Cockerell OC, Hart YM, Sander JW, Shorvon SD. The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies. Epilepsy Res. 18(3), 249-260 (1994).
66. Heaney D. Epilepsy at work: evaluating the cost of epilepsy in the workplace. Epilepsia 40(Suppl. 8), 44-47 (1999).
67. Jacoby A, Buck D, Baker G, McNamee P, Graham-Jones S, Chadwick D. Uptake and costs of care for epilepsy: fndings from a UK regional study. Epilepsia 39(7), 776-786 (1998).
68. Duh MS, Cahill KE, Paradis PE, Cremieux PY, Greenberg PE. The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence. Expert Opin. Pharmacother. 10(14), 2317-2328 (2009).
69. Jobst BC, Holmes GL. Prescribing antiepileptic drugs: should patients be switched on the basis of cost? CNS Drugs 18(10), 617-628 (2004).
70. Heaney DC, Begley CE. Economic evaluation of epilepsy treatment: a review of the literature. Epilepsia 43(Suppl. 4), 10-16 (2002).
71. Begley CE, Beghi E. The economic cost of epilepsy: a review of the literature. Epilepsia 43(Suppl. 4), 3-9 (2002).
72. Strzelczyk A, Reese JP, Dodel R, Hamer HM. Cost of epilepsy: a systematic review. Pharmacoeconomics 26(6), 463-476 (2008).
73. LeLorier J, Duh MS, Paradis PE et al. Economic impact of generic substitution of lamotrigine: projected costs in the US using fndings in a Canadian setting. Curr. Med. Res. Opin. 24(4), 1069-1081 (2008).
74. Duh MS, Andermann F, Paradis PE, Weiner J, Manjunath R, Cremieux PY. The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine. Dis. Manag. 10(4), 216-225 (2007).
75. Zachry WM, Doan QD, Clewell JD, Smith BJ. Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes. Epilepsia 50(3), 493-500 (2008).
76. Helmers SL, Paradis PE, Manjunath R et al. Economic burden associated with the use of generic antiepileptic drugs in the United States. Epilepsy Behav. 18(4), 437-444 (2010).
77. Kesselheim AS, Misono AS, Lee JL et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 300(21), 2514-2526 (2008).
78. de Wolf P, Brouwer WB, Rutten FF. Regulating the Dutch pharmaceutical market: improving effciency or controlling costs? Int. J. Health Plann. Manage. 20(4), 351-374 (2005).
79. Tootelian DH, Royer J, Johnson RC. Providing incentives to control health care costs and remain competitive in the marketplace: a pilot study. Health Mark. Q. 15(2), 87-99 (1997).
80. Epilepsy Action. Position Statement-Consistency of Supply. British Epilepsy Association, Leeds, UK (2005).
81. Haymarket Publishing. MIMS. Haymarket Publishing Ltd, London, UK (2006).
82. Scottish Intercollegiate Guidelines Network. Diagnosis and Management of Epilepsy in Adults. A National Guideline. Royal College of Physicians, Edinburgh, UK (2003).
83. Perucca E, Albani F, Capovilla G, Bernardina BD, Michelucci R, Zaccara G. Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs. Epilepsia 47(Suppl. 5), 16-20 (2006).
84. Krämer G, Dennig D, Schmidt D et al. [Generics in antiepileptic drug therapy: what has to be considered?]. Akt. Neurol. 32, 275-278 (2005).
85. LFCE. Recommendations on the Use of Generics for the Treatment of Epilepsy. French Chapter of the International League Against Epilepsy, Bron, France (2008).
86. Brainwave. Submission to the Oireachtas Joint Committee on Health and Children in respect of the proposed substitution by generic AEDs (anti-epileptic drugs) of branded AEDs. Epilepsy News 37, 4-5 (2008).
87. AFSSAPS. Substitution of Antiepileptic Medications. Press release, Agence française de sécurité sanitaire des produits de santé, Paris, France (2008).
88. Antiepileptic drugs: the drawbacks of generic substitution. Lancet Neurol. 9(3), 227 (2010).
89. Heaney DC, Sander JW. Antiepileptic drugs: generic versus branded treatments. Lancet Neurol. 6(5), 465-468 (2007).
90. Manjunath R, Davis KL, Candrilli SD, Ettinger AB. Association of antiepileptic drug nonadherence with risk of seizures in adults with epilepsy. Epilepsy Behav. 14(2), 372-378 (2009).
91. Johnston A, Stafylas P, Stergiou GS. Effectiveness, safety and cost of drug substitution in hypertension. Br. J. Clin. Pharmacol. 70, 320-334 (2010).
92. Gagne JJ, Avorn J, Shrank WH, Schneeweiss S. Reflling and switching of antiepileptic drugs and seizure-related events. Clin. Pharmacol. Ther. 88(3), 347-353 (2010).
93. Liow K. Understanding patients' perspective in the use of generic antiepileptic drugs: compelling lessons for physicians to improve physician/patient communication. BMC Neurol. 9, 11 (2009).
94. Hattingh HL. Pharmacists' responsibility and potential liability regarding generic substitition. Med. Law 28(4), 697-704 (2009).
95. European Commission Enterprise Directorate-General. Marketing authorisation. In: Procedures for Marketing Authorisation (Volume 2A). European Commission Enterprise Directorate-General, Brussels (2006).
96. Borgherini G. The bioequivalence and therapeutic effcacy of generic versus brand-name psychoactive drugs. Clin. Ther. 25(6), 1578-1592 (2003).
97. Nashef L, Fish DR, Garner S, Sander JW, Shorvon SD. Sudden death in epilepsy: a study of incidence in a young cohort with epilepsy and learning diffculty. Epilepsia 36(12), 1187-1194 (1995).
98. Kitson A, Shorvon S. Clinical Standards Advisory Group. Services for Patients with Epilepsy. Department of Health, London, UK (2000).
99. Shorvon SD. The epidemiology and treatment of chronic and refractory epilepsy. Epilepsia 37(Suppl. 2), S1-S3 (1996).
100. Hanna NJ, Black M, Sander JW et al. The National Sentinel Clinical Audit of Epilepsy-Related Death. Epilepsy-Death in the Shadows. The Stationery Offce, Norwich, UK (2002).
101. Epilepsy: safety, excess mortality and sudden death. Epilepsia 44(Suppl. 6), 19-20 (2003).
102. Schmidt D, Loscher W. Uncontrolled epilepsy following discontinuation of antiepileptic drugs in seizure-free patients: a review of current clinical experience. Acta Neurol. Scand. 111(5), 291-300 (2005).
103. Tomson T, Walczak T, Sillanpaa M, Sander JW. Sudden unexpected death in epilepsy: a review of incidence and risk factors. Epilepsia 46(Suppl. 11), 54-61 (2005).
104. CPMP. Guideline on the investigation of bioequivalence www.ema.europa.eu/pdfs/human/qwp/140198enrev1fn.pdf (Accessed 1 March, 2010).
105. FDA. Greater access to generic drugs www.fda.gov/Drugs/ResourcesForYou/ Consumers/ucm143545.htm (Accessed 1 March, 2010).
106. Schachter SC. Working partners: achieving your treatment goal www.epilepsyfoundation.org/epilepsyusa/equal.cfm (Accessed 1 March, 2010).